Generix Group : 1st Half 2016/2017 Results: Ebitda of 6%

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Generix Group : 1st Half 2016/2017 Results: Ebitda of 6% of revenue

1st Half 2016/2017 Results Ebitda of 6% of revenue

Paris, November 28, 2016 - Generix Group, Industrial, Logistical and Retail Ecosystems provider with leading Collaborative Software Solutions, today issued its interim financial statements for the six-month period ended September 30, 2016.

SaaS revenue growth of 32%

The strategic change of direction over the last few years has enabled SaaS, the primary activity in terms of generating growth, to show an increase of 32% over the first half of the 2016/2017 year.

Generix Group thus confirms its position as an application service provider with nearly 50% of its revenue generated by its SaaS model (including the associated Conseil & Services activities). 

The loyalty of the established base also enabled Generix Group to show a growth of 25% in license sales.

  Six months ended September 30, Variation
IFRS consolidated accounts, in millions of Euros 2016 2015 M€ %
Revenues 29,6 27,3 2,3 9%
Which licenses 2,1 1,7 0,4 25%
Which maintenance 8,7 8,8 -0,1 -1%
Which SaaS 10,6 8,0 2,6 32%
Which Consulting Services 8,2 8,8 -0,6 -7%
Operational expenses / other income -28,5 -25,7 -2,8 11%
Profit (loss) from current operations 1,1 1,5 -0,4 -29%
Other operational income and expenses -0,4 -0,3 -0,1 43%
Profit (loss) from operations 0,6 1,2 -0,6 -47%
Financial expenses -0,1 -0,1 0,0 36%
Loss before income taxes 0,5 1,1 -0,6 -54%
Income taxes benefit -0,2 -0,4 0,2 -56%
Net result after tax 0,3 0,7 -0,4 -53%
Net result 0,3 0,7 -0,4 -54%
  Six months ended September 30, Variation
EBITDA  in millions of euros 2016 2015 proforma 2015 published M€ %
Revenues   29,6  27,3 27,3 2,3 9%
Other income from operations   0,6  0,6 0,6 0,0 2%
Cost of goods sold -  0,4  -0,5 -0,5 0,1 -11%
Other purchases and external expenses -  9,7  -8,8 -8,8 -0,9 11%
Taxes and similar payments -  0,7  -0,6 -0,6 0,0 6%
Personnel costs -  16,5  -15,3 -15,3 -1,3 8%
Other expenses on operations -  0,3  -0,2 -0,2 -0,1 36%
Reversals of used provisions during the period -  0,0  0,0 0,0 0,0 N/A
Capitalized production -  0,8  -0,5 -0,5 -0,4 74%
Sales commissions spread (2)   -  0,0 -0,6 0,0 N/A
EBITDA (1)   1,8  2,1 1,5 -0,3 -14%
  1. EBITDA = current operating income + net provisions on current assets + net provisions for risks and charges + depreciation on fixed assets - capitalized production costs.  
  2. In order to interpret this economic performance in a pertinent way, the staggering of sales bonuses has been included in the EBITDA figure since March 31, 2016.

Over the half year, the Group showed an Ebitda of 6% of its revenue (or €1.8 million). The drop in Ebitda compared to revenue is primarily due to the reinforcement of our sales force.

The net impact of activated software expenses, net depreciation charges and provisions amounts to -€0.7 million, bringing the recurring operating income to €1.1 million. 

After figuring in the other operating expenses, which primarily correspond with the costs of acquisitions, the operating income amounts to €0.6 million.

International development cash flow

  

  Six months ended September 30, Variation
Net debt, in millions of Euros 2016 2015 M€ %
Cash and cash equivalents, end of period 1,6 -1,5 3,1 -206%
Short-term and long-term portions of financial obligations -12,5 -5,8 -6,7 115%
Net debt -10,9 -7,3 -3,6 49%
  Six months ended September 30, Variation
Consolidated statements of cash flows, in millions of Euros 2016 2015 M€ %
Net income adjusted by non-cash items 1,7 1,8 0,0 -2%
Change in working capital -8,1 -7,9 -0,3 3%
Net cash by operating activities -6,4 -6,1 -0,3 5%
Net cash used in investing activities -2,1 -2,1 0,0 2%
Free cash flow -8,5 -8,2 -0,4 4%
Net cash by financing activities 4,6 -1,4 6,0 -439%
Net increase in cash and cash equivalent -3,9 -9,5 5,6 -59%
Cash and cash equivalent, end of period 1,6 -1,5 3,1 -204%

The cash flow statement expresses the flows between March 31 and September 30, 2016 in comparison to the same period last fiscal year. Between these two dates, the working capital requirements increased due to paying for annual maintenance contracts invoiced at the start of the calendar year and accounted for in revenues over the entire year.

The cash flow of the last half of the year was marked by an increase of €6 million in net treasury corresponding with financing activities, and in particular the taking out of a middle-term loan of €4.5 million as part of the takeover of the Sologlobe Logistiques Inc. company, which was finalized on October 3, 2016. This figure may be compared with the reimbursement of €1.4 million over the same half-year period of the previous financial year.

Prospects

Generix Group confidently faces the second half of the year. The acquisition of the Canadienne Sologlobe Logistiques Inc. company enable the Group to develop internationally since it represents a direct approach to the North American continent, representing nearly half of the world's market in supply chain software investments.

Supplemental and non-IFRS Financial Information

Supplemental non-IFRS information (above-mentioned as Ebitda or net debt) presented in this press release are subject to inherent limitations. It is not based on any comprehensive set of accounting rules or principles and should not be considered as a substitute for IFRS measurements. Also, the Company's supplemental non-IFRS financial information may not be comparable to similarly titled non-IFRS measures used by other companies.

***

The Half-Year Financial Report at September 30, 2016 is available for download at the address: http://www.generixgroup.com/fr/liste/rapports-financiers/

Next press release: January 30, 2017 after closing of the stock exchange Revenues for the third quarter of financial year 2016/2017

Contacts

Ludovic Luzza Chief Financial Officer Tel: +33 (0)1 77 45 42 80 lluzza@generixgroup.com www.generixgroup.com   Stéphanie Stahr CM-CIC Market Solutions Tel: +33 (0)1 53 48 80 57 stephanie.stahr@cmcic.fr www.cmcics.com

About Generix Group

Software editor of collaborative applications, Generix Group helps its customers to face digital enterprise challenges: facilitating buying journeys, building a digital supply chain, and dematerializing all data flows. By building differentiating services, Generix Group optimizes the overall performance of the company within its ecosystem, enabling it to meet customers' new expectations.

Over 5,000 international players have contributed to establishing Generix Group as a European leader, with close to €58 million in turnover

For more information, visit www.generixgroup.com

Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...4229b4b389

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LV Petroleum Expands Footprint with Key Acquisitions

Updated Category News Views 0

LV Petroleum's Bold Moves in July Ever seen a company expand across four states in a blink? LV Petroleum's been hustling like a player with a fresh hand of aces. They shut July down with restaurant openings and a fancy new travel center under their belt in states as spread out as Arizona, Texas, Nevada, and Ohio. Now that's a wide net they're casting, all in the name of...

Continue Reading
ECRI Welcomes Safety Expert Meshkati to Its Board

Updated Category News Views 1

The Safety Maverick Steps into Healthcare They've gone and done it—appointed a rockstar of systems safety to ECRI's Board of Trustees. Professor Najmedin Meshkati, who's practically been around every major industrial accident of the past few decades, is about to shake things up. Imagine the guy who's dissected calamities like the BP Texas City Refinery explosion and the...

Continue Reading
PGI's Award-Winning Febreze Cabin Air Filters Shines Again

Updated Category News Views 9

A Breath of Fresh Air for the Auto Aftermarket How often do you even think about the quality of air inside your vehicle? If you're like most folks, it's not often. But Premium Guard Inc. (PGI) has been busy changing that narrative. Their Febreze Cabin Air Filters just snagged the 2026 MOTOR Top 20 Awards, proving that they're not just a pretty face in the automotive...

Continue Reading
Taiwan's Machine Emerges as Heavy-Tonnage Game Changer

Updated Category News Views 2

Every once in a while, the machinery scene gets rocked by something that genuinely raises eyebrows, and it seems Chuan Lih Fa Machinery Works Co., Ltd. (CLF) has just delivered one of those moments. This isn't just any old injection molding machine—it's Taiwan's very first 5000-ton giant, crafted with robust precision and dispatched straight to a major U.S. logistics...

Continue Reading
Courtesy Auto Group Expands with Tucson Dealerships Buy

Updated Category News Views 4

Moving Pieces in the Automotive Puzzle Here's one for the books, folks. Automotive dealership chessboard gets another shuffle. Scott Gruwell, the big wheel behind Courtesy Automotive Group, has snatched up Watson Chevrolet and Infiniti of Tucson. Just one more notch in someone's power belt—operations now rolling under new banners as Courtesy Chevrolet and Courtesy...

Continue Reading
Ribbonwire Ranch Hits Sheetz Milestone with Campaign

Updated Category News Views 3

Where Beef Snacks Meet Road Tales Just a year ago, Ribbonwire Ranch, a small Texas-based beef snack producer, made its debut at Sheetz stores. Now, they're not just another brand on the shelf; they're weaving tales from the road with their latest venture, the "Dashboard Diaries" campaign. If you're wondering how a beef snack producer finds itself in an eight-week...

Continue Reading
CAPR Faces Lawsuit and FDA Delay: Investor Alert

Updated Category News Views 0

Trouble Brewin' for Capricor Investors Buckle up, folks. Capricor Therapeutics (NASDAQ: CAPR) is caught in a storm, facing not just the lengthy arm of law with a securities class action, but also a seemingly endless wait with the FDA's decision on their lead product. We're talking serious implications for anyone with skin in the game. The FDA's Delayed Blessing So the...

Continue Reading
Regeneron: Investors Face Class Action Over Study Flaws

Updated Category News Views 0

Regeneron Investors Grit Teeth Amid Lawsuit Drama The gloves are off in the pharmaceutical battleground, folks. Investors who thought they were riding the big wave with Regeneron Pharmaceuticals (NASDAQ: REGN) are now staring down the barrel of a class action lawsuit. It seems the company’s been caught in a storm of legal action following allegations of misleading...

Continue Reading
Max Stock Expands with Strategic Logistics Center

Updated Category News Views 1

Expansion in Full Swing In a move that might get tongues wagging in the boardrooms across Israel, Max Stock Limited (TASE: MAXO) just signed a hefty lease for a logistics center in Ofakim. This isn't just a modest expansion—it's a jaw-dropper at about 45,000 square meters. We're talking about a major upgrade that'll beef up their logistical backbone as they continue...

Continue Reading
Beyoncé Drops Remastered 'B'DAY'; Celebrates Legacy

Updated Category News Views 0

Every so often, an artist comes around who's not just making music but shifting the very landscape of their genre. Beyoncé isn't just marking her birthday today; she's reminding the world of a career-defining moment with the release of her remastered deluxe version of 'B'DAY'. This isn't just a stroll down memory lane; it's a full-blown revival of an era that reshaped...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding the Options Market Trends for Nano Nuclear Energy

Updated Category News Views 109

Exploring Current Trends in the Options Market for Nano Nuclear Energy Recent movements among financial giants suggest a notable bearish sentiment surrounding Nano Nuclear Energy. Analyzing the options history for Nano Nuclear Energy (NNE), we have identified 12 unusual trades that indicate evolving market perspectives. In our detailed assessment, we discovered that...

Continue Reading
NeoImmuneTech Unveils Breakthrough Results for CAR-T Therapy

Updated Category News Views 186

Promising Developments in CAR-T Therapy with NT-I7 NeoImmuneTech, Inc. has achieved significant advancements in enhancing CAR-T cell therapies, which are innovative treatments designed to combat cancer. Recent interim results from the Phase 1b clinical trial demonstrate the potential benefits of combining NT-I7 (efineptakin alfa) with CAR-T therapy, highlighting its...

Continue Reading
Owkin Teams Up with AstraZeneca to Transform Breast Cancer Testing

Updated Category News Views 156

Owkin made headlines back in 2024 when it teamed up with AstraZeneca, looking to revolutionize breast cancer diagnostics by developing an advanced tool for pre-screening gBRCA mutations. Traders were quick to pick up on this collaboration, given the critical nature of BRCA testing and its potential market impact. But let’s peel back the layers on this deal. Partnership...

Continue Reading
Medical Express Ambulance Faces Data Breach Investigation

Updated Category News Views 342

Understanding the Data Breach Investigation Edelson Lechtzin LLP, a prominent class action law firm, is currently looking into data privacy concerns affecting customers of Medical Express Ambulance, Inc. (MedEx). MedEx has reported potential unauthorized access to its network, raising significant alarm regarding the safety of customer data. Medical Express Ambulance, Inc....

Continue Reading
Discover the 2026 Best Wellness Employer Survey Insights

Updated Category News Views 117

Wellness Workdays Unveils the 2026 Best Wellness Employer Survey In a significant move towards enhancing employee health and wellness, Wellness Workdays has launched the 2026 Best Wellness Employer survey. This initiative invites organizations to showcase their dedication to improving workplace well-being through sustainable practices and measurable results. Collaboration...

Continue Reading